Personalized Medicine Biomarkers Market Expected To Reach $58.79 Billion By 2030 As Growth Accelerates At 17% CAGR
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Personalized Medicine Biomarkers Market Growth From $31.34 Billion In 2026 To $58.79 Billion By 2030 At A CAGR Of 17%
The market for biomarkers in personalized medicine has experienced significant expansion over the past few years. By 2025, its value reached $26.73 billion, and this figure is projected to climb to $31.34 billion by 2026, reflecting a compound annual growth rate (CAGR) of 17.3%. This historic growth has been driven by advancements in genomic research, a growing number of cancer cases, the rise of targeted treatment approaches, broader adoption of molecular diagnostic tools, and supportive regulatory frameworks for precision medicine.
The personalized medicine biomarkers market is projected to experience substantial expansion in the upcoming years, reaching $58.8 billion by 2030 with a compound annual growth rate (CAGR) of 17.0%. This forecasted growth is driven by the expansion of personalized therapeutics, a growing need for early disease detection, advancements in pharmacogenomics, increased funding for biomarker discovery, and broader application in non-oncology indications. Key trends shaping this period include the rising adoption of precision treatment strategies, the growing use of biomarkers in oncology care, the increasing integration of companion diagnostics, the development of both predictive and prognostic biomarkers, and a heightened emphasis on monitoring treatment responses.
Download A Free Sample Report For Comprehensive Market Insights:
Personalized Medicine Biomarkers Market Development Factors: Which Trends Are Supporting Demand?
The rising incidence of chronic illnesses is anticipated to boost the personalized medicine biomarkers market in the coming years. Chronic diseases are long-term health conditions that develop slowly, last a year or longer, and demand ongoing medical care or restrict everyday activities. This increase is mainly driven by poor lifestyle habits, unhealthy diets, insufficient physical activity, and elevated stress levels. Personalized medicine biomarkers facilitate tailored treatments for chronic conditions by pinpointing effective therapies, forecasting disease progression, and reducing negative effects using individual genetic and molecular insights. For example, as reported in February 2024 by the World Health Organization (WHO), a health authority based in Switzerland, new cancer cases worldwide are projected to exceed 35 million by 2050, marking a 77% rise from the roughly 20 million cases recorded in 2022. Consequently, the growing frequency of chronic diseases is fueling expansion in the personalized medicine biomarkers market.
Personalized Medicine Biomarkers Market Categorization By Product Type And Application
The personalized medicine biomarkers market covered in this report is segmented –
1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types
2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications
3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring
4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users
Subsegments:
1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers
2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers
3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers
4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers
Personalized Medicine Biomarkers Market Transformation Trends: Which Innovations Are Driving Change?
Key players in the personalized medicine biomarkers sector are concentrating on securing regulatory clearances, such as companion diagnostic approvals, to advance precision oncology by efficiently linking patients to targeted therapies. This type of approval is an official endorsement from a regulatory body, like the FDA, for a diagnostic tool created to pinpoint individuals who will gain the most from a specific therapeutic product or who face a higher chance of experiencing harmful side effects. In August 2024, for example, Illumina, Inc.—a biotechnology firm based in the United States—obtained FDA approval for its cancer biomarker test along with two companion diagnostics. The test employs next-generation sequencing (NGS) to detect genetic mutations in tumor cells, allowing physicians to choose the best treatments according to each patient’s unique biomarkers. This authorization represents a notable step forward in precision oncology, with the goal of enhancing the speed and precision of treatment decisions for cancer patients, thereby boosting personalized medicine approaches.
Personalized Medicine Biomarkers Market Company Landscape And Strategic Competition
Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.
Access The Complete Personalized Medicine Biomarkers Market Report:
Personalized Medicine Biomarkers Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
